Cambiar Investors’s Regeneron Pharmaceuticals REGN Stock Holding History

Cambiar Investors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$35.9M	Sell	57,573 -610	-1%	-$415K	1.56%	28
2026 Q1	$45M	Sell	58,183 -1,980	-3%	-$1.52M	2.08%	19
2025 Q4	$46.4M	Buy	60,163 +1,069	+2%	+$726K	2.07%	21
2025 Q3	$33.2M	Sell	59,094 -3,376	-5%	-$1.91M	1.51%	32
2025 Q2	$32.8M	Buy	62,470 +12,160	+24%	+$6.79M	1.38%	32
2025 Q1	$31.9M	Buy	+50,310	New	+$34.6M	1.35%	34

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Cambiar Investors's REGN Position: Q2 2026 in Review

Cambiar Investors reduced its Regeneron Pharmaceuticals (REGN) stake by 1% in Q2 2026, selling an estimated $415K and leaving 57,573 shares worth $35.9M. The position accounts for 1.56% of the portfolio, ranked #28.

Cambiar Investors first reported a position in REGN in Q1 2025 and has held it in 6 quarters since. The position peaked at $46.4M in Q4 2025. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Cambiar Investors held 57,573 shares of Regeneron Pharmaceuticals worth $35.9M as of Q2 2026.
Cambiar Investors sold 610 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $415K.
Regeneron Pharmaceuticals made up 1.56% of Cambiar Investors's portfolio in Q2 2026, its #28 holding.
Cambiar Investors first reported a position in Regeneron Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
Cambiar Investors's Regeneron Pharmaceuticals position peaked at $46.4M in Q4 2025.
1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Cambiar Investors's 13F filing for Q2 2026, filed 31 Jul 2026.